Speaking of news, just after a seller got rid of about 225,000 shares at the bid, news was released.

Shares went from .048 to as low as .035, then:

"Nuvilex Advances Release of Citroxin(TM) Antiviral Surface Cleaner to Help Combat Swine Flu
4/29/2009 10:43 AM - PR Newswire

CHERRY HILL, N.J., April 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ --

Nuvilex, Inc. (OTC Bulletin Board: NVLX), an emerging healthcare consumer products company, today announced that it will advance the release of Citroxin to domestic and international health agencies including hospitals, clinics, and medical offices as well as other at risk institutions and companies, such as schools and airlines. Nuvilex has proof of Citroxin's effectiveness in eliminating swine influenza virus (SIV; H1N1 subtype) and avian influenza virus (AIV; H9N9 subtype) on surface areas but has not yet submitted Citroxin for EPA approval as an antiviral agent. Citroxin samples will be provided at no cost and the Company will provide technical assistance. Citroxin is being released early as the current Swine Flu outbreak requires the best products be deployed to combat the growing epidemic.

Independent laboratory testing of Citroxin showed a 100% kill rate for the "big six" bacterial health threats, including E. coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, Streptococcus, and Black Mold. Citroxin is an EPA registered germicidal composition (EPA registration number 82723-1) and is patented in the US and world wide (US 7,439,218 and WIPO 2007/038265 A3).

Interested parties should contact A. Peter Morello III, Ph.D., Director of Research at Nuvilex via a specially set up email address: citroxin@nuvilex.com for product information and specifications as well as to request a sample.

"Given the seriousness of the threat of the spread of swine flu, we believe it is our duty to push hard to make Citroxin available as soon as possible," said Martin E. Schmieg, Chairman and CEO of Nuvilex, Inc. "Much of the innovation in science and technology for combating big problems comes from small companies such as Nuvilex. Moving our discoveries into the world takes resources - investment capital, which has all but disappeared from the market because of the current economic downturn. If Citroxin takes root as envisioned, demand will outpace our manufacturing capabilities and it will be necessary for us to seek a commercial partner to move the product quickly into the marketplace."

Citroxin is a eco-friendly surface cleaner. The Company's viral testing to date has been led by Sagar M. Goyal, D.V.M., Ph.D. at the University of Minnesota. Dr. Goyal has investigated the use of Citroxin to treat viral subtypes of SIV (H1N1). In Dr. Goyal's first experiment, his team evaluated the ability of Citroxin (dilutions of 1:10 and 1:100) to inhibit the replication of SIV H1N1 in vitro. Compared to the controls, high concentrations of Citroxin (1:10 dilution) were found to be virucidal for SIV growing in MDCK (Madin-Darby canine kidney) cells.

The Company, in conjunction with international based academic researchers, has also treated H9N9 AIV with Citroxin. In the AIV H9N9 experiments, Citroxin also served as a better virucidal agent when it received a smaller viral challenge (1000, 100, and 10 tissue culture infectious dose50, or TCID50, of virus).

"Although Citroxin is not yet proven to be immunogenic, experiments do suggest that Citroxin can serve as an effective cleaner or disinfectant for surfaces that may have come into contact with SIV, AIV, or other types of virus particles," said Dr. Morello. "We are ready, willing and able to help the global public health community in combating the swine flu outbreak."

Now, if any takers like the product, ....

go